---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-26-000256"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2026-08-03T20:09:43+00:00"
generated_at: "2026-08-03T20:11:32.839140+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vertex Q2 revenue $3.33B (+12% YoY); raises FY revenue guidance to $13.1-13.2B; announces $10B Crinetics acquisition

## Summary
- Total revenue $3.33B, up 12% YoY; GAAP net income $1.1B, non-GAAP $1.2B.
- Full-year 2026 revenue guidance raised to $13.1-13.2B from $12.95-13.1B.
- CASGEVY revenue $76M (+151% YoY); JOURNAVX revenue $50M (quadrupled YoY).
- Entered agreement to acquire Crinetics for $85/share, total equity value ~$10B; close expected Q3 2026.
- Povetacicept PDUFA date Nov 30, 2026 for IgAN.

## SEC filing metadata
- accession: 0000875320-26-000256
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2026-08-03T20:09:43+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532026000256/0000875320-26-000256-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532026000256/vrtx-20260803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-26-000256
- JSON: https://secwatch.observer/filing/0000875320-26-000256.json
- Plain text: https://secwatch.observer/filing/0000875320-26-000256.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.